

1 **Repeated population-based surveys of antibodies against SARS-**  
2 **CoV-2 in Southern Brazil**

3  
4 Mariângela F Silveira, Aluísio J D Barros, Bernardo L Horta, Lúcia C Pellanda, Odir A  
5 Dellagostin, Claudio J Struchiner, Marcelo N Burattini, Andréia R M Valim, Evelise M  
6 Berlezi, Jeovany M Mesa, Maria Letícia R Ikeda, Marília A Mesenburg, Marina  
7 Mantesso, Marinel M Dall'Agnol, Raqueli A Bittencourt, Fernando P Hartwig, Ana M B  
8 Menezes, Fernando C Barros, Pedro C Hallal\*<sup>#</sup>, Cesar G Victora<sup>#</sup>

9  
10 (#) Joint last authors

11  
12 **Universidade Federal de Pelotas, Brazil** (Dr. Pedro C Hallal, Prof. Aluísio J D Barros,  
13 Prof. Bernardo L Horta, Prof. Mariângela F Silveira, Prof. Odir A Dellagostin, Dr.  
14 Fernando P Hartwig, Prof. Ana B Menezes, Prof. Fernando C Barros, Prof. Cesar G  
15 Victora), **Fundação Universidade Federal de Ciências de Saúde de Porto Alegre, Brazil**  
16 (Prof. Lúcia C Pellanda, Profa Marília A Mesenburg), **Fundação Getúlio Vargas and**  
17 **Universidade do Estado do Rio de Janeiro, Brazil** (Prof. Claudio J Struchiner),  
18 **Universidade de São Paulo, Brazil and Universidade Federal de São Paulo, Brazil**  
19 (Prof. Marcelo N Burattini), **Universidade de Santa Cruz do Sul, Brazil** (Profa. Andréia R  
20 M Valim), **Universidade de Ijuí, Brazil** (Profa Evelise M Berlezi), **IMED - Passo Fundo,**  
21 **Brazil**, (Prof. Jeovany M Mesa), **Universidade do Vale do Rio dos Sinos, Brazil** (Profa.  
22 Maria Letícia R Ikeda), **Universidade de Caxias do Sul, Brazil** (Profa. Marina Mantesso),  
23 **Universidade Federal de Santa Maria, Brazil** (Profa. Marinel M Dall'Agnol), **Secretaria**  
24 **Municipal de Saúde de Uruguaiana, Brazil** (Raqueli A Bittencourt).

25  
26 **Correspondence to:** Pedro C Hallal, Marechal Deodoro 1160 – 96020-220 - Pelotas, RS,  
27 Brazil – Phone (fax): +55 53 3284-1300 - Email: prchallal@gmail.com

28  
29 **Funding:** This work started through the Data Committee created by the State of Rio  
30 Grande do Sul government to fight the COVID-19 pandemics. The tests used in the  
31 study have been provided by the Brazilian Ministry of Health. Funding for data  
32 collection was provided by UNIMED Porto Alegre, Instituto Cultural Floresta and  
33 Instituto Serrapilheira.

34

35 **ABSTRACT**

36

37 Population based data on COVID-19 are urgently needed for informing policy decisions,  
38 yet few such studies are available anywhere, as most surveys rely on self-selected  
39 volunteers. In the Brazilian State of Rio Grande do Sul (population 11.3 million), we are  
40 carrying out fortnightly household surveys in nine of the largest cities. Multi-stage  
41 probability sampling was used in each city to select 500 households, within which one  
42 resident was randomly chosen for testing. The Wondfo lateral flow rapid test for  
43 detecting antibodies against SARS-CoV-2 has been validated in four different settings,  
44 including our own, with pooled estimates of sensitivity (84.8%, 95% CI 81.4%;87.8%)  
45 and specificity (99.0%, 95% CI 97.8%;99.7%), which are within the acceptable range for  
46 epidemiological studies. In the first wave of the study (April 11-13), 4,188 subjects  
47 were tested, of whom two were positive (0.0477%; 95% confidence interval (CI)  
48 0.0058%;0.1724%). In the second round (Apr 25-27) there were six positive subjects  
49 (0.1333%; 95% CI 0.0489%;0.2900%). We also tested family members of positive index  
50 cases, and nine out of 19 had positive results. Testing of reported COVID-19 cases  
51 according to RT-PCR confirmed that the test was highly sensitive under field  
52 conditions. The epidemic is at an early stage in the State, as the first case was reported  
53 on Feb 28, and by Apr 30, 50 deaths were registered. Strict lockdown measures were  
54 implemented in mid-March, and our results suggest that compliance was high, with full  
55 or near full compliance rates of 79.4% in the first and 71.7% in the second round. As far  
56 as we know, this is the only large population anywhere undergoing regular household  
57 serological surveys for COVID-19. The results show that the epidemic is at an early  
58 phase, and findings from the next rounds will allow us to document time trends and  
59 propose Public Health measures.

## 60 INTRODUCTION

61

62 Despite calls for population-based data on COVID-19,<sup>1</sup> there have been remarkably  
63 few household seroprevalence surveys anywhere, and none in Latin America.<sup>2</sup> In Rio  
64 Grande do Sul, the southernmost state in Brazil (population 11.3 million), the first case  
65 of COVID-19 was diagnosed on February 29, 2020. As of April 30, 1,466 confirmed  
66 cases (129 per 1,000,000 inhabitants) and 50 deaths had been reported  
67 (<http://ti.saude.rs.gov.br/covid19/>). It is important to remark that in the state, as also  
68 in Brazil, only persons with moderate to severe symptoms had been tested, using PCR  
69 to detect SARS-Cov-2. The state and most municipal governments issued strong social  
70 distancing policies in mid-March, including closures of schools, shops and services,  
71 except for businesses deemed to be essential.

72

73 Other than studies based on convenience samples, such as individuals who  
74 volunteered to be tested, supermarket customers, or blood donors, there are few  
75 general population sample surveys in the literature. In a national study in Iceland<sup>3</sup>,  
76 one of the three groups of participants was recruited through random sampling of the  
77 population, but only about one third of those invited were tested. In this group, 13 of  
78 2283 persons tested positive (0.6%; 95% CI 0.3;0.9) in quantitative real-time  
79 polymerase-chain-reaction (qRT-PCR) assays. A national household study in Austria  
80 used random sampling to invite households to participate. Of the households  
81 contacted, 77% or 2,197 declared their willingness to participate, and 1,541 persons  
82 were successfully tested. Assuming two persons per household, those tested  
83 correspond to about 30% of the intended sample. The study found a prevalence of  
84 0.33% (95% CI 0.12;0.76%) using qRT-PCR, or 5 individuals out of those tested.<sup>4</sup>  
85 Smaller studies in hot spots for COVID-19 showed prevalence of 14% the German city  
86 of Gangelt<sup>5</sup> and 3% in the Italian village of Vò.<sup>6</sup>

87

88 As expected, studies based on volunteers found higher prevalence, as was the case for  
89 the first study in Iceland (0.9%)<sup>3</sup>, the population screening in South Korea (2.1%)<sup>7</sup> and  
90 two studies in California: prevalence of 1.5% in Santa Clara county<sup>8</sup> and 4.1% in Los  
91 Angeles County.

92 <http://publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=2328>

93

94 Starting on April 11-13, we set out to test the presence of antibodies against SARS-  
95 CoV-2 in population-based samples of 500 individuals in each of nine sentinel cities in  
96 the state, with a total sample of 4,500. The same methodology was used in a second  
97 round in the same cities on April 25-27, and subsequent rounds are planned to take  
98 place every two weeks in order to monitor how the pandemic is evolving.

99

100

101 **METHODS**

102

103 The state of Rio Grande do Sul is divided by the National Institute of Geography and  
104 Statistics in eight intermediary regions (Figure 1). The main city in each region was  
105 selected for the study. In the main metropolitan region, we selected the State Capital,  
106 Porto Alegre, and Canoas, the second largest city in the metropolitan area. Populations  
107 ranged from 78,915 in Ijuí to 1,409,351 in Porto Alegre  
108 (<https://cidades.ibge.gov.br/brasil/rs/panorama>).

109

110 **Figure 1. Location of the nine sentinel cities.**



111

112

113 We used multistage sampling to select 50 census tracts with probability proportionate  
114 to size in each sentinel city, and 10 households at random in each tract based on  
115 census listings updated in 2019. All household members were listed at the beginning of  
116 the visit, and one individual was randomly selected through an app used for data  
117 collection. The survey waves took place on April 10-12 and 25-27.

118

119 The Statewide sample of 4,500 individuals allows estimating a prevalence levels of 3%  
120 and 10% with margins of error of 0.5 and 1.0 percent points, respectively.

121

122 In the first wave, interviewers had listings of 35 households in each tract. Any refusals  
123 at household level led to selection of the next household in the list, and so on until 10  
124 households were included. In the second wave, field workers went to the house visited  
125 in the first wave, and then selected the tenth household to its right. In case of refusal,  
126 the next household to the right side was selected. In the case of acceptance at the  
127 household level but the index individual refused to provide a sample, a second  
128 member was selected. If this person also refused, the field workers moved on to the  
129 next household in the list.

130

131 Prevalence of antibodies was assessed with a rapid test using finger prick blood  
132 samples - the WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou,  
133 China). This test detects immunoglobulins of both IgG and IgM isotypes specific to  
134 SARS-CoV-2 antigens in a lateral flow assay. The capture reagent consists of an  
135 unspecified viral antigen immobilized at a defined position on a nitrocellulose  
136 membrane. Following the introduction of the sample, a solution containing labelled  
137 detector anti-immunoglobulin monoclonal antibodies is added. If the test is valid, a  
138 control line appears on the kit's window. If this line is not visible, the test is deemed  
139 inconclusive, which is very uncommon. A positive result is triggered by binding of the  
140 detector antibody to any serum immunoglobulins immobilized on the viral antigen,  
141 and is visible as a second colored line. Two drops of blood from a pinprick are sufficient  
142 to detect the presence of antibody.

143 Four independent validation studies are available for the rapid test. Its sensitivity and  
144 specificity are 86.4% and 99.6% according to the manufacturer, using samples  
145 collected from 361 confirmed cases and 235 negative  
146 controls([https://en.wondfo.com.cn/product/wondfo-sars-cov-2-antibody-test-lateral-  
147 flow-method-2/](https://en.wondfo.com.cn/product/wondfo-sars-cov-2-antibody-test-lateral-flow-method-2/)). The tests were purchased in bulk by the Brazilian government, being  
148 earmarked for use in population surveys and surveillance programs. An initial  
149 validation study was carried out by the National Institute for Quality Control in Health  
150 (INCQS, Oswaldo Cruz Foundation, RJ, Brazil) using 18 qRT-PCR positive and 77  
151 negative serum samples. The reported sensitivity was 100.0% (95% confidence interval  
152 (CI) 81.5;100.0%), while specificity was 98.7% (95% CI 93.0;100.9%). Recently,  
153 Whitman and colleagues<sup>9</sup> evaluated 10 different lateral flow assays using as  
154 specimens plasma or serum samples from symptomatic SARSCoV-2 RT-PCR-positive  
155 individuals and 108 pre-COVID-19 negative controls. Sensitivity of the Wondfo test was  
156 81.5% (95% CI 70.0-90.1%) among 65 patients with a positive RT-PCR 11 or more days  
157 before the test, and specificity was 99.1% (95% CI 94.9;100.0%). Of the 10 tests  
158 studied, the Wondfo test was one of the two lateral flow tests with the best  
159 performance. Lastly, we carried out our own validation study, based on 83 volunteers  
160 with a positive qRT-PCR result 10 days or more before the rapid test. This analysis  
161 showed a sensitivity of 77.1% (95% CI 66.6;85.6%). We also analysed 100 sera samples  
162 collected in 2012 from participants of the 1982 Pelotas (Brazil) Birth Cohort Study<sup>10</sup>

163 and found 98 negative results, yielding a specificity estimate of 98.0% (95% CI  
164 93.0;99.8%). By pooling the results from the four separate validations studies,  
165 weighted by sample sizes, sensitivity is estimated at 84.8% (95% CI 81.4%;87.8%) and  
166 specificity at 99.0% (95% CI 97.8%;99.7%).

167

168 Participants answered short questionnaires including sociodemographic information  
169 (sex, age, schooling and skin color), COVID-19-related symptoms, use of health  
170 services, compliance with social distancing measures and use of masks. Field workers  
171 used tablets or smartphones to record the full interviews, register all answers, and  
172 photograph the test results. All positive or inconclusive tests were read by a second  
173 observer, as well as 20% of the negative tests. If the index subject in a household had a  
174 positive result, all other family members were invited to be tested.

175

176 Interviewers were tested and found to be negative for the virus, and were provided  
177 with individual protection equipment that was discarded after visiting each home.  
178 Ethical approval was obtained from the Brazilian's National Ethics Committee (process  
179 number 30415520.2.0000.5313), with written informed consent from all participants.  
180 Positive cases were reported to the statewide COVID-19 surveillance system. The study  
181 protocol was published prior to the first wave of data collection.<sup>11</sup> Data will become  
182 publicly available upon request from the corresponding author 30 days after publication.

183

184 In the analyses reported in the body of this article, we analyzed the surveys as if they  
185 included simple random samples from the population, using the exact binomial  
186 method for confidence intervals. We calculated absolute (in percent points) and  
187 relative differences between the two survey waves regarding the prevalence of  
188 infection. P-values were calculated using Cochran's Q heterogeneity test, implemented  
189 as fixed-effects meta-regression, which also yielded confidence intervals for the  
190 differences. More complex analyses with allowances for the sampling design,  
191 population weights and corrections for the specificity and sensitivity of the rapid test,  
192 are included in the web annex. All analyses were performed using R version 3.6.1  
193 (<https://www.r-project.org/>). The "metafor" package was used to compare the  
194 prevalence between surveys.

195

196 **RESULTS**

197

198 Out of the planned 4,500 interviews, it was possible to test 4,188 individuals in the first  
199 round. The number of tests carried out included 500 in each of five cities (Pelotas,  
200 Passo Fundo, Santa Cruz, Caxias), 396 in Porto Alegre, 332 in Canoas, 499 in  
201 Urugaiana and 461 in Santa Maria. In the last three cities, the desired sample size was  
202 not completed due to logistic difficulties resulting from the need to complete the  
203 survey in a 3-day period. Refusals, requiring the selection of the next household in the  
204 census tract listing, ranged from 5.4% in Ijuí to 26.9% in Santa Maria, with a median of  
205 17.9% in the nine cities. In the second round, it was possible to obtain 500 interviews  
206 in each of the nine cities.

207

208 Table 1 shows the characteristics of individuals who provided blood samples. Both  
209 samples were similar in terms of sex, age, skin color and schooling distributions.  
210 Although the nine sentinel cities are not representative of the state as a whole, the  
211 comparison shows what the samples had higher proportions of women and of older  
212 persons than the state as a whole. Young children were particularly underrepresented.  
213 Up-to-date information on schooling is not available for the State.

214

215 Of the 4,188 individuals tested in the first round, 10 had inconclusive results and only  
216 two (0.0477%; 95% confidence interval (CI) 0.0058%;0.1724%) tested positive, one  
217 each in the cities of Pelotas and Urugaiana. In the second round, there were two  
218 inconclusive results and six positive subjects (0.1333%; 95% CI 0.0489%;0.2900%). The  
219 absolute prevalence difference between the second and first waves was equal 0.086  
220 percent point (95% CI -0.400;0.211; P=0.181), and the ratio was equal to 2.793 (95% CI  
221 0.564;13.831, P=0.208).

222

223 Given the small numbers of subjects who tested positive, we focus the presentation on  
224 unadjusted results. The web annex provides results from more complex analyses, all of  
225 which produced results that are highly comparable to those reported here.

226

227 Regarding social distancing measures, 20.6% of respondents reported leaving home on  
228 a daily basis, 58.3% leaving home occasionally for essential activities, and 21.1%  
229 staying at home all the time in the first phase, and 28.3%, 53.4% and 18.3%,  
230 respectively, in the second phase.

231

232 The households of the eight positive cases in the two phases included other 20  
233 residents. Of these, 19 were tested; the rapid test showed nine positive, eight  
234 negative, and two inconclusive results. One positive case lived alone. Among the other  
235 seven, four had at least another positive individual in their families.

236

237 **Table 1. Sociodemographic characteristics of the two samples in nine cities and of**  
 238 **the State population.**  
 239

	ROUND 1	ROUND 2	STATE POPULATION <sup>12,13</sup>
SEX	%	%	%
Male	41.7	40.5	48.7
Female	58.3	59.5	51.3
AGE			
0-9	3.6	2.6	12.3
10-19	5.4	5.1	12.6
20-29	12.2	11.4	15.1
30-39	15.3	16.9	15.1
40-49	15.5	14.6	13.3
50-59	17.9	17.9	12.9
60-69	16.4	17.9	10.2
70-79	9.4	10.2	5.7
80+	4.3	3.4	2.9
SKIN COLOR			
White	76.6	75.9	81.5
Brown	15.8	16.2	13.0
Black	6.5	6.6	5.2
Other	1.1	1.3	0.3
EDUCATION			
Primary or less	37.4	34.1	Not available
Secondary	29.8	31.8	
University or higher	32.8	34.1	

240

241

242

243 As an additional check on how the rapid test performed under field work conditions,  
 244 we conducted two separate assessments. The first was during the validation study in  
 245 Porto Alegre, where 83 RT-PCR positive individuals were tested in the field using the  
 246 rapid test. As described in the Methods section, 64 of these had positive results with  
 247 the rapid test. Second, a more limited assessment entailed asking the coordinators of  
 248 field work in different cities whether they were aware of any RT-PCR positive  
 249 individuals in their communities. Four persons were identified and tested, all of whom  
 250 had positive results in the rapid test.

251

252



253 **DISCUSSION**

254

255 This is the first report on repeated population-based surveys for the detection of SARS-  
256 CoV-2 antibodies. With two weeks interval we were able to perform antibody tests on  
257 representative samples in nine sentinel cities in Rio Grande do Sul State in Southern  
258 Brazil.

259

260 Based on reported death rates by April 30, 2020, Rio Grande do Sul is one of the six  
261 states, out of 27, with the lowest mortality, of 4 per million, well below Rio de Janeiro  
262 (46 per million) or Sao Paulo (49 per million). Amazonas state (92 per million) shows  
263 the highest death rates. The national mortality rate is estimated at 26 per million.

264 (<https://covid.saude.gov.br/>)

265

266 Taking our present results at face value, there would be 477 cases per million  
267 inhabitants (95% confidence interval 58-1,719 cases) in the first wave, compared to 62  
268 reported cases per million, as of April 14. According to the results of the second wave  
269 (April 25-27), there would be 1,333 cases per million inhabitants (95% CI 489;2900)  
270 compared to 128 reported cases per million as of April 30. Additional estimates, taking  
271 into account corrections for the sample design, population weighting and adjustment  
272 for sensitivity and specificity, are provided in the web annex.

273

274 Important concerns have been issued about rapid serological tests, but these mostly  
275 refer to their use in making clinical decisions,<sup>14</sup> and on issuing “immunity passports”<sup>15</sup>  
276 for individuals who are assumed to have developed immunity. Both of these  
277 circumstances refer to individual-level diagnoses based on rapid tests. Use of rapid  
278 tests for population-based estimates, and particularly for monitoring trends over time,  
279 is a different issue for which rapid tests with less than perfect sensitivity and specificity  
280 may be acceptable. The Wondfo lateral flow test used in our analyses underwent four  
281 different validation studies, being able to correctly identify 5 out of every 6 RT-PCR  
282 confirmed cases, and 99 out of 100 individuals without SARS-CoV-2 antibodies. Among  
283 10 lateral flow tests recently assessed by Whitman and colleagues<sup>9</sup>, it was among the  
284 two with the best performance. Our finding of positive results for 10 of 13 family  
285 members of the six index individuals who tested positive confirms that the  
286 performance of the rapid test was adequate under field conditions.

287

288 The limitations of our analyses include the restriction of the sample to sentinel cities  
289 that jointly account for 31% of the state’s population, while smaller towns and rural  
290 areas were not included. Second, antibody tests result in many false negatives for  
291 recent infections, particularly within the first two weeks since contagion, and thus  
292 prevalence reflects levels of infection a week or two prior to the survey, about 15 days  
293 after the first case was reported in the state. The non-response rate at household

294 level, estimated at 17.9%, was low compared to other population-based studies,<sup>3,4</sup> or  
295 to studies based on volunteers. Our samples had fewer children than expected, which  
296 was probably due to their reluctance to undergo a finger prick when randomly selected  
297 within the household; in these cases, a second person was randomly selected and if  
298 that person also refused the household was replaced.

299

300 Lastly, our results were at the lower range of the 95% confidence interval for the false  
301 positive rate, which in the pooled estimate from four validation studies was estimated  
302 at 1.0% (95% CI 0.3%;2.2%). In these studies, specificity was measured in frozen  
303 samples. Whitman and colleagues, in their analyses of 10 lateral flow tests, observed  
304 *“moderate-to-strong positive bands in several pre-COVID-19 blood donor specimens,*  
305 *some of them positive by multiple assays, suggesting the possibility of non-specific*  
306 *binding of plasma proteins, non-specific antibodies, or cross-reactivity with other*  
307 *viruses.”*<sup>9</sup> Our results on family clustering show that - out of the seven index cases who  
308 lived alone - four had family members who also tested positive. These four individuals  
309 are most likely true positives, thus suggesting that up to four of the remaining index  
310 cases with positive results, out of 8,689 individuals, might represent false positive  
311 results. The test’s specificity would then be equal to 99.95% (95% CI 99.88;99.99%).

312

313 Our finding of low prevalence is consistent with an early phase of the pandemic,  
314 coupled with high compliance with social distancing measures, as confirmed by our  
315 own results. Such a low prevalence level is compatible with other population-based  
316 studies: 0.6% in Iceland<sup>3</sup> and 0.3% in Austria,<sup>4</sup> which is close to Northern Italy which  
317 was strongly hit by the pandemic. One should note that in both studies about 2/3 of  
318 those invited failed to participate, compared to our own non-response rate of 17.9%.  
319 Our results are not comparable with those based on self-selected volunteers.

320

321 The surveys are being partly funded by the state and national governments of Brazil.  
322 Survey results were disseminated, two days after the completion of data collection  
323 round, in press briefings with the presence of the state governor, who is making use of  
324 the information to guide stay-at-home and other policies. Results from the next rounds  
325 of our study – planned for May 8-10 and 22-23 - will allow us to follow the dynamics of  
326 the pandemic in the state, especially when social restriction measures are starting to  
327 be relaxed in most municipalities.

## 328 References

329

- 330 1. Pearce N, Vandenbroucke JP, VanderWeele TJ, Greenland S. Accurate Statistics on  
331 COVID-19 Are Essential for Policy Guidance and Decisions. *American journal of public health*  
332 2020: e1-e3.
- 333 2. Barreto ML, Barros AJD, Carvalho MS, et al. [What is urgent and necessary to inform  
334 policies to deal with the COVID-19 pandemic in Brazil?]. *Rev Bras Epidemiol* 2020; **23**: e200032.
- 335 3. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic  
336 Population. *The New England journal of medicine* 2020.
- 337 4. Institute for Social Research and Consulting Ogris & Hofinger GmbH (SORA). COVID-19  
338 Prevalence, 2020.
- 339 5. Regalado A. Blood tests show 14% of people are now immune to covid-19 in one town  
340 in Germany. 2020. [https://www.technologyreview.com/2020/04/09/999015/blood-tests-](https://www.technologyreview.com/2020/04/09/999015/blood-tests-show-15-of-people-are-now-immune-to-covid-19-in-one-town-in-germany/)  
341 [show-15-of-people-are-now-immune-to-covid-19-in-one-town-in-germany/](https://www.technologyreview.com/2020/04/09/999015/blood-tests-show-15-of-people-are-now-immune-to-covid-19-in-one-town-in-germany/) (accessed April 27,  
342 2020.
- 343 6. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus  
344 in Italian village. *BMJ* 2020; **368**: m1165.
- 345 7. Ministry of Health and Welfare (South Korea). Coronavirus disease 19, Republic of  
346 South Korea. 2020. <http://ncov.mohw.go.kr/en>.
- 347 8. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa  
348 Clara County, California. *medRxiv* 2020: 2020.04.14.20062463.
- 349 9. Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2  
350 serological assays. (*unpublished*) 2020.
- 351 10. Horta BL, Gigante DP, Goncalves H, et al. Cohort profile update: the 1982 Pelotas  
352 (Brazil) Birth Cohort Study. *International journal of epidemiology* 2015; **44**(2): 441-e.
- 353 11. Hallal P, Horta B, Barros A, et al. Evolução da prevalência de infecção por COVID-19 no  
354 Rio Grande do Sul: inquéritos sorológicos seriados. . *Cien Saude Colet* 2020.
- 355 12. Instituto Brasileiro de Geografia e Estatística. Pesquisa nacional por amostra de  
356 domicílios : síntese de indicadores 2015. Rio de Janeiro: IBGE, 2016.
- 357 13. Instituto Brasileiro de Geografia e Estatística. Projeções da População. 2019.  
358 [HTTPS://WWW.IBGE.GOV.BR/ESTATISTICAS/SOCIAIS/POPULACAO/9109-PROJEC-AO-DA-](https://www.ibge.gov.br/estatisticas/sociais/populacao/9109-projecao-da-populacao.html?=&t=resultados)  
359 [POPULACAO.HTML?=&t=RESULTADOS](https://www.ibge.gov.br/estatisticas/sociais/populacao/9109-projecao-da-populacao.html?=&t=resultados) (accessed April 30, 2020.
- 360 14. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests  
361 for COVID-19. 2020. [https://www.who.int/news-room/commentaries/detail/advice-on-the-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)  
362 [use-of-point-of-care-immunodiagnostic-tests-for-covid-19](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19) (accessed April 30, 2020.
- 363 15. World Health Organization. "Immunity passports" in the context of COVID-19. 2020.  
364 [https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-](https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19)  
365 [covid-19](https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19) (accessed April 30, 2020.

366